Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
24.88
+0.34 (1.39%)
At close: Sep 5, 2025, 4:00 PM
24.86
-0.02 (-0.08%)
After-hours: Sep 5, 2025, 7:59 PM EDT
Pfizer Revenue
Pfizer had revenue of $14.65B in the quarter ending June 29, 2025, with 10.31% growth. This brings the company's revenue in the last twelve months to $63.83B, up 13.53% year-over-year. In the year 2024, Pfizer had annual revenue of $63.63B with 6.84% growth.
Revenue (ttm)
$63.83B
Revenue Growth
+13.53%
P/S Ratio
2.21
Revenue / Employee
$788,062
Employees
81,000
Market Cap
141.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
| Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
| Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
| Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
| Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PFE News
- 1 day ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (Sept. 2025) - Seeking Alpha
- 2 days ago - Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks - Seeking Alpha
- 3 days ago - Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
- 3 days ago - 10 Stocks And ETFs 'On Sale' This Month - Benzinga
- 4 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 4 days ago - Pfizer defends COVID-19 vaccine effectiveness after Trump remarks - Reuters
- 5 days ago - Pfizer: Pipeline Monetization Shows Great Promise - Rich Yields Pending Re-Rating - Seeking Alpha
- 5 days ago - Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer - GlobeNewsWire